Trial Outcomes & Findings for Communicating Health Information and Improving Coordination With Primary Care (NCT NCT03104543)

NCT ID: NCT03104543

Last Updated: 2024-03-06

Results Overview

Assess the overall probability of having any undertreated condition based on home visit measurements and blood testing

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

347 participants

Primary outcome timeframe

1 year

Results posted on

2024-03-06

Participant Flow

Participant milestones

Participant milestones
Measure
Education
Educational materials Education: 30 minute education session; 15 minute booster session at 4 months
Test Results
Test results only; with delayed access to the experimental materials Test results only: The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
Overall Study
STARTED
175
172
Overall Study
COMPLETED
126
138
Overall Study
NOT COMPLETED
49
34

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Communicating Health Information and Improving Coordination With Primary Care

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Education
n=175 Participants
Educational materials Education: 30 minute education session; 15 minute booster session at 4 months
Test Results
n=172 Participants
Test results only; with delayed access to the experimental materials Test results only: The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
Total
n=347 Participants
Total of all reporting groups
Age, Continuous
41.3 years
STANDARD_DEVIATION 9.9 • n=5 Participants
39.4 years
STANDARD_DEVIATION 8.9 • n=7 Participants
40.3 years
STANDARD_DEVIATION 9.4 • n=5 Participants
Sex: Female, Male
Female
89 Participants
n=5 Participants
93 Participants
n=7 Participants
182 Participants
n=5 Participants
Sex: Female, Male
Male
86 Participants
n=5 Participants
79 Participants
n=7 Participants
165 Participants
n=5 Participants
Race/Ethnicity, Customized
White non-Hispanic
146 Participants
n=5 Participants
147 Participants
n=7 Participants
293 Participants
n=5 Participants
Race/Ethnicity, Customized
Other race/ethnicity
29 Participants
n=5 Participants
25 Participants
n=7 Participants
54 Participants
n=5 Participants
Undertreated hypertension
68 Participants
n=5 Participants
55 Participants
n=7 Participants
123 Participants
n=5 Participants
Undertreated dyslipidemia
79 Participants
n=5 Participants
80 Participants
n=7 Participants
159 Participants
n=5 Participants
Undertreated diabetes
22 Participants
n=5 Participants
19 Participants
n=7 Participants
41 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 1 year

Population: Analysis population includes only those with 12 month follow-up data

Assess the overall probability of having any undertreated condition based on home visit measurements and blood testing

Outcome measures

Outcome measures
Measure
Education
n=126 Participants
Educational materials Education: 30 minute education session; 15 minute booster session at 4 months
Test Results
n=138 Participants
Test results only; with delayed access to the experimental materials Test results only: The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c >=5.7% or Fasting Glucose >=100; if Diabetes, Hemoglobin A1c >=7%)
Number of participants with undertreated hypertension at follow-up
49 participants
59 participants
Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c >=5.7% or Fasting Glucose >=100; if Diabetes, Hemoglobin A1c >=7%)
Number of participants with undertreated dyslipidemia at follow-up
43 participants
41 participants
Undertreatment of Hypertension (>=140/90 mmHg), Dyslipidemia (LDL >=160 mg/dL or Triglyceride >=150 mg/dL), and/or Glucose Intolerance (if Prediabetes, Hemoglobin A1c >=5.7% or Fasting Glucose >=100; if Diabetes, Hemoglobin A1c >=7%)
Number of participants with undertreated prediabeties / diabetes at follow-up
48 participants
54 participants

SECONDARY outcome

Timeframe: 1 year

Population: Analysis population includes only those with 12 month follow-up data

Childhood cancer survivors' self-reported health knowledge (measured by questionnaire)

Outcome measures

Outcome measures
Measure
Education
n=126 Participants
Educational materials Education: 30 minute education session; 15 minute booster session at 4 months
Test Results
n=138 Participants
Test results only; with delayed access to the experimental materials Test results only: The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
Health Knowledge
Number participants who recalled prior anthracycline exposure correctly at follow-up
51 Participants
49 Participants
Health Knowledge
Number participants who recalled prior radiotherapy exposure correctly at follow-up
105 Participants
113 Participants

SECONDARY outcome

Timeframe: 1 year

Population: Analysis population includes only those with 12 month follow-up data

Childhood cancer survivors' self-efficacy towards managing their healthcare (measured by questionnaire). Scale is based on work by: "Schwarzer R, Jerusalem M. Generalized Self-Efficacy scale. In: Weinman J, Wright S, Johnston M, editors. Measures in Health Psychology: A User's Portfolio. Casual and Control Beliefs. Windsor, UK:NFER-NELSON; 1995. p. 35-7." Specifically, the study used an adapted version of this scale with 5-items (4-point Likert scale) that measure perceived ability to set-goals, cope and recover from setbacks. The mean raw score for each participant was multiplied by 10 and converted to a T-score per survey developers' documentation, with 50 representing the US adult population mean, with a standard deviation of 10, and higher scores reflecting higher self-efficacy.

Outcome measures

Outcome measures
Measure
Education
n=126 Participants
Educational materials Education: 30 minute education session; 15 minute booster session at 4 months
Test Results
n=138 Participants
Test results only; with delayed access to the experimental materials Test results only: The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
Self-efficacy
49.5 T-score
Standard Deviation 11.8
50.5 T-score
Standard Deviation 11.3

SECONDARY outcome

Timeframe: 1 year

Population: Number of primary care providers

Healthcare providers' health knowledge and self-efficacy related to the care of childhood cancer survivors (measured by questionnaire). Specific question assesses providers' self-perceived skill in taking care of such survivors, rated from 1 (strongly disagree) to 5 (strongly agree).

Outcome measures

Outcome measures
Measure
Education
n=77 Participants
Educational materials Education: 30 minute education session; 15 minute booster session at 4 months
Test Results
n=79 Participants
Test results only; with delayed access to the experimental materials Test results only: The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
Primary Care Provider Attitudes
3.37 units on a scale
Standard Deviation 1.23
3.46 units on a scale
Standard Deviation 1.13

Adverse Events

Education

Serious events: 0 serious events
Other events: 0 other events
Deaths: 5 deaths

Test Results

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Eric Chow

Fred Hutchinson Cancer Center

Phone: 206-667-7724

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place